ClinicalTrials.gg
WithdrawnNCT05043987Updated Sep 7, 2023

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

A Phase 1 interventional study of CPO102 in Pancreatic Cancer and Gastric Cancer, sponsored by Conjupro Biotherapeutics, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Conjupro Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
New IND sponsor to initiate a separate study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available.

Read the detailed description

This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available. All patients must have failed standard first or later lines of systemic therapy.

The study design overview is presented below. The study will consist of 2 parts, Part A and Part B. Part A will explore once every 3 weeks (Q3W) dosing per standard 3+3 dose escalation design. Upon attaining a RP2D, Part B will commence in 2 groups, in approximately 15 patients with advanced pancreatic cancer and 15 patients with advanced gastric including gastric esophageal junction cancers. Part B will seek to confirm the RP2D and will also seek early signals of efficacy in the selected cancer patient populations.

02

Conditions studied

  • Pancreatic Cancer
  • Gastric Cancer

Keywords

  • Claudin 18.2 ADC
  • Phase 1
  • CPO102
  • Pancreatic Cancer
  • Gastric Cancer
03

In context

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Conjupro Biotherapeutics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Applicable to all patients in both Part A and Part B of the study:

  • Pathological diagnosis (histological) of pancreatic or gastric including esophageal junction cancers.
  • Patient must provide archived tissue block or formalin-fixed paraffin-embedded (FFPE) slides or fresh prior to start of treatment.
  • Positive claudin 18.2 tumor expression defined as ≥50% of tumor cells demonstrating moderate-to-strong membranous staining (2+/3+) by IHC assay performed on sections of tumor derived from formalin fixed paraffin block.
  • Adequate organ function.
  • >12 weeks.
  • Age ≥18 years.
  • performance status 0 or 1 at screening.
  • Ability to understand the nature of this study, comply with protocol requirements, and give written .
  • Patients of : All female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before study entry.

Specific criteria for Part A:

  • Disease progression or relapse following conventional chemotherapy:

    1. Pancreatic cancer
    2. Gastric cancer (including GEJ cancer)

Specific criteria for Part B:

  • suitable for imaging and efficacy tracking as defined by 1.1
  • Disease progression or relapse following conventional chemotherapy:

    1. Pancreatic cancer
    2. Gastric cancer (including GEJ cancer)

Exclusion criteria

Exclusion Criteria:

  1. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to baseline or to (CTCAE) grade ≤1, with the exception of alopecia, ≥grade 2 neuropathy, or to the levels dictated in the inclusion/exclusion criteria.
  2. Patient has participated in any research study and is being screened for participation within a period of 5 half-lives or 4 weeks, whichever is longer, of the last dose of the investigational therapy.
  3. History of severe infusion reaction with monoclonal antibody treatment.
  4. Active or latent or active (test within 8 weeks of screening), or any uncontrolled infection at screening.
  5. positive test within 8 weeks of screening.
  6. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
  7. Presence of other active cancers, or history of treatment for invasive cancer ≤3 years. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, noninvasive) are eligible, as are patients with history of nonmelanoma skin cancer.
  8. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  9. Active central nervous system (CNS) disease involvement, defined by cerebrospinal fluid (CSF) cytology, magnetic resonance imaging (MRI) or computerized tomography (CT); patients with asymptomatic are eligible if participants have been clinically stable for at least 4 weeks prior to the first dose of study drug and do not require interventions such as surgery, radiation or any therapy for management of symptoms related to CNS disease.
  10. Peripheral neuropathy Grades ≥ 2.
  11. Active ocular surface disease at baseline (based on ophthalmic evaluation).
  12. Pregnant or nursing (lactating) women.
  13. Patients who received claudin 18.2 targeting agents previously.
  14. Patients who have received or will receive coronavirus disease 2019 (COVID-19) vaccine within 72 hours prior to the first dose of study drug.
  15. Prior radiotherapy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part A

    Part A will follow the standard 3+3 dose-escalation design and will be enrolled at dose levels of CPO102 at (0.5, 1, 1.8, 2.5, 3.5, 4.5, 5.5 mg/kg). Each subject group will receive one dose of CPO-102 every 3 weeks (1 cycle=21 days=1 treatment). For each cohort, the decision whether to dose-escalate will be made once all patients have been enrolled into the cohort and the last patient enrolled has been followed for 21 days (3-week DLT observation period).

    Drug: CPO102

  • Experimental
    Part B-Arm 1

    Upon attaining a RP2D, Part B-Arm 1 will include approximately 15 patients with pancreatic cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).

    Drug: CPO102

  • Experimental
    Part B-Arm 2

    Upon attaining a RP2D, Part B-Arm 2 will include approximately 15 gastric (including gastric esophageal junction) cancer patients. This subject group will receive multiple cycles of a weekly dose of CPO-102 (1 cycle=21 days=1 treatment).

    Drug: CPO102

Interventions

  • DrugCPO102

    Anti-claudin 18.2 Antibody-MMAE Drug Conjugate

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period.

    DLTs are assessed during the first cycle (21 days) in each cohort to determine maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

    Time frame: through study completion, an average of 3 year

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by relationship.

    TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0.

    Time frame: through study completion, an average of 3 year

  2. Number of participants with clinically significant changes in vital signs

    Number of participants with clinically significant changes in vital signs

    Time frame: through study completion, an average of 3 year

  3. Number of participants with clinically significant changes in clinical laboratory tests

    Number of participants with clinically significant changes in clinical laboratory tests

    Time frame: through study completion, an average of 3 year

  4. CPO102 pharmacokinetics: Area under the concentration time curve over the dosing interval.

    CPO102 pharmacokinetics: Area under the concentration time curve over the dosing interval.

    Time frame: through study completion, an average of 3 year

  5. CPO102 pharmacokinetics: Maximum concentration of the drug (Cmax)

    CPO102 pharmacokinetics: Maximum concentration of the drug (Cmax)

    Time frame: through study completion, an average of 3 year

  6. CPO102 pharmacokinetics: Time to maximum concentration (Tmax)

    CPO102 pharmacokinetics: Time to maximum concentration (Tmax)

    Time frame: through study completion, an average of 3 year

  7. CPO102 pharmacokinetics: Elimination half-life (t1/2)

    CPO102 pharmacokinetics: Elimination half-life (t1/2)

    Time frame: through study completion, an average of 3 year

  8. CPO102 pharmacokinetics: Clearance (CL)

    CPO102 pharmacokinetics: Clearance (CL)

    Time frame: through study completion, an average of 3 year

  9. CPO102 Objective response rate (ORR)

    ORR is defined as the proportion of patients in whom a complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 is observed as best overall response.

    Time frame: through study completion, an average of 3 year

  10. CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA)

    CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA)

    Time frame: through study completion, an average of 3 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Nov 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2021
First posted
Sep 14, 2021
StartActual
Nov 16, 2022
Primary completionActual
Nov 16, 2022
CompletionActual
Nov 16, 2022
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05043987
Lead sponsor
Conjupro Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 14, 2021
Start date
Nov 16, 2022
Primary completion
Nov 16, 2022
Completion
Nov 16, 2022
Last update
Sep 7, 2023

Study contacts

Jiangfeng Su, MD, PhD
study director · Conjupro Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion